Intensification of chelating-therapy in patients with thalassemia major

Klinische Padiatrie

Volumn 217, Issue 3, 2005, Pages 120-125

  Laws, Hans Jürgen ^a,b   Gobel U ^a   Christaras, A ^a   Janssen G ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cardial function; Central venous line; Deferoxamin; Ferritin; SQUID

Indexed keywords

CHELATING AGENT; DEFEROXAMINE; FERRITIN;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CHELATION THERAPY; CHILD; CLINICAL ARTICLE; FEMALE; FERRITIN BLOOD LEVEL; HEART FUNCTION; HEMOSIDEROSIS; HUMAN; IRON CHELATION; MALE; PATIENT COMPLIANCE; PROPHYLAXIS; QUALITY OF LIFE; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; AGE FACTORS; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; FERRITINS; HUMANS; INFUSION PUMPS; INFUSIONS, INTRAVENOUS; IRON CHELATING AGENTS; LIVER FUNCTION TESTS; PATIENT COMPLIANCE; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 18944369499     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-836506     Document Type: Article

References (23)

1. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, Hilson AJ. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 1990; 84: 113-117
2. 2* cardiovascular magnetic resonance. Br J Haematol 2004; 127: 348-355
3. Beratis S. Noncompliance with iron chelation therapy in patients with beta thalassaemia. J Psychosom Res 1989; 33: 739-745
4. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-573
5. Cario H, Stahnke K, Sander S, Kohne E. Epidemiological situation and treatment of patients with thalassemia major in Germany: results of the German multicenter beta-thalassemia study. Ann Hematol 2000; 79: 7-12
6. Cazzola M, Borgna-Pignatti C, de Stefano P, Bergamaschi G, Bongo IG, Dezza L, Avato F. Internal distribution of excess iron and sources of serum ferritin in patients with thalassemia. Scand J Haematol 1983; 30: 289-296
7. Cohen AR, Mizanin J, Schwartz E. Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy. J Pediatr 1989; 115: 151-155
8. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000; 95: 1229-1236
9. de Virgiliis S, Sanna G, Cornacchia G, Argiolu F, Murgia V, Porcu M, Cao A. Serum ferritin, liver iron stores, and liver histology in children with thalassaemia. Arch Dis Child 1980; 55: 43-45
10. Fosburg MT, Nathan DG. Treatment of Cooley's anemia. Blood 1990; 76: 435-444
11. Freedman MH, Grisaru D, Olivieri N, MacLusky I, Thorner PS. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. Am J Dis Child 1990; 144: 565-569
12. Herold A, Rothe K, Woller T, Bierbach U, Bennek J. Early and late complications after implantation of central venous catheters. Klin Padiatr 2003; 215: 24-29
13. Hoch C, Gobel U, Janssen G. Psychosocial support of patients with homozygous beta-thalassaemia. Klin Padiatr 2000; 212: 216-219
14. Jensen PD, Jensen FT, Christensen T, Ellegaard J. Non-invasive assessment of tissue iron overload in the liver by magnetic resonance imaging. Br J Haematol 1994; 87: 171-184
15. Mitnick JS, Bosniak MA, Megibow AJ, Karpatkin M, Feiner HD, Kutin N, Natta F Van, Piomelli S. CT in B-thalassemia: iron deposition in the liver, spleen, and lymph nodes. AJR Am J Roentgenol 1981; 136: 1191-1194
16. Nielsen P, Kordes U, Fischer R, Engelhardt R, Janka GE. SQUID-biosusceptometry in iron overloaded patients with hematologic diseases. Klin Padiatr 2002; 214: 218-222
17. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739-761
18. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331: 574-578
19. Pootrakul P, Josephson B, Huebers HA, Finch CA. Quantitation of ferritin iron in plasma, an explanation for non-transferrin iron. Blood 1988; 71: 1120-1123
20. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 1996; 88: 705-713
21. Wali YA, Taqi A, Deghaidi A. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections. Pediatr Hematol Oncol 2004; 21: 453-460
22. Wang WC, Ahmed N, Hanna M. Non-transferrin-bound iron in long-term transfusion in children with congenital anemias. J Pediatr 1986; 108: 552-557
23. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S. Survival and causes of death in thalassaemia major. Lancet 1989; 2: 27-30